TheMathCompany Announces $50 Million Investment from Brighton Park Capital
13.1.2022 14:00:00 EET | Business Wire | Press release
TheMathCompany, a global data analytics and data engineering firm that partners with companies to enhance their analytics capabilities, today announced that it has secured $50 million in investments. The round of funding was led by Brighton Park Capital, an investment firm that specializes in collaborating with growth-stage software, healthcare, and tech-enabled services businesses. Existing investor, Arihant Patni, also participated in this round. The minority investment will accelerate TheMathCompany’s expansion in the US and EU markets, as well as enhance its next-generation, proprietary platform, Co.dx, which drives value for businesses through analytics at speed and scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220113005153/en/
(Photo: Business Wire)
Founded by industry leaders, Sayandeb Banerjee, Aditya Kumbakonam, and Anuj Krishna, TheMathCompany is a high-growth firm that employs nearly 1,000 data scientists, data engineers, and domain experts. The company represents and partners with Fortune 500 customers across the CPG, Retail, Pharma, Automotive, Technology, and Manufacturing industries in the US, UK, and EU. Enabling clients with a diverse set of capabilities powered by Co.dx, the organization implements data science and engineering initiatives across business functions, including marketing, supply chain, R&D, and finance. TheMathCompany’s hybrid model unifies Co.dx with a comprehensive consulting approach to deliver custom, cutting-edge analytics and AI-driven assets, helping customers implement successful and strategic business decisions.
“We are thrilled to announce Brighton Park Capital’s investment,” said Sayandeb Banerjee, CEO of TheMathCompany. “The firm’s deep technology sector expertise and proven track record of scaling global enterprises will be instrumental to our growth.”
“We look forward to partnering with TheMathCompany’s founders and the entire team to support their continued growth,” said Mark F. Dzialga, Managing Partner of Brighton Park Capital. “TheMathCompany is positioned for continued success as it strengthens its brand recognition and expands in the US and EU markets, supporting customers on their missions to capture value through data analytics.”
“TheMathCompany is poised to become one of the largest data and analytics consultancies in the world, supported by a world-class team of data engineers and scientists, and complemented by the power of the Co.dx platform to deliver more value, faster, for customers. I couldn’t be more excited to partner with Sayandeb, Aditya, and Anuj on the significant opportunities ahead,” said Jeff Machlin, Partner of Brighton Park. As part of the transaction, Jeff Machlin will join the Board of Directors.
“While most players in the industry have taken decades to grow to our size, we have built this strong foundation within five years. Brighton Park Capital’s partnership will further accelerate our plans to become the world’s leading global analytics consultancy,” said Aditya Kumbakonam, Chief Customer & Growth Officer at TheMathCompany. “As we grow and evolve, this investment will help us continue to bring elevated service and consistent quality to our customers.”
Anuj Krishna, Chief Product Officer at TheMathCompany, said, “With Brighton Park Capital as investors, we are excited to continue creating better opportunities for our people to grow their careers, while expanding the business globally. TheMathCompany will continue to invest heavily in Co.dx – a significant and meaningful differentiator in our journey to help enterprises scale and solve problems faster.”
TheMathCompany employs leading data scientists and engineers globally while also recruiting emerging talent from top-tier universities. New hires participate in a comprehensive onboarding and training program with the company’s in-house growth accelerator, Co.ach. The program is designed to help employees upskill across analytics disciplines and adapt to the industry’s ever-changing dynamics. In addition to fostering continued career development, the firm incentivizes employees with a stock ownership program, enabling them to participate in TheMathCompany’s continued growth and future success.
Avendus Capital served as financial advisor and Shardul Amarchand Mangaldas & Company served as legal counsel to TheMathCompany. Bharucha & Partners and Paul Weiss served as legal counsel to Brighton Park Capital.
About TheMathCompany
TheMathCompany is a global data analytics and data engineering firm that partners with Fortune 500 and equivalent organizations to enhance their analytics capabilities, using IP-led assets, talent, and processes to deliver accelerated and human-centric solutions. TheMathCompany has been recognized as one of the fastest-growing analytics firms in the world and has been featured among global high-growth firms by Nikkei-FT-Statista’s 2021 Growth Champions list, NASSCOM’s AI Gamechangers 2021 report, and the Everest Group’s PEAK Matrix® Assessment 2021. Providing a holistic range of services across data engineering, science, and unique project delivery, the company is disrupting the analytics industry. For more information about TheMathCompany, please visit www.themathcompany.com.
About Brighton Park Capital
Brighton Park is a Greenwich, CT-based investment firm that specializes in software, healthcare, and technology-enabled services. The firm invests in companies that provide highly innovative solutions in partnership with great management teams. Brighton Park brings purpose-built value-add capabilities that match the unique requirements of each of its companies. For more information about Brighton Park, please visit www.bpc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005153/en/
Contact information
For TheMathCompany:
Vignesh Subramanyam
vignesh.subramanyam@themathcompany.com
For Brighton Park Capital:
Emily Claffey / Alex Harron
Sard Verbinnen & Co
BrightonPark-SVC@SARDVERB.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom